European Archives - Page 834 of 899 - European Medical Journal

Continue
3rd July 2015

Subgroup analysis of the MCL-002 (SPRINT) trial of lenalidomide in relapsed/refractory MCL

At the 20th Congress of the European Hematology Association (EHA), Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, discusses the…
3rd July 2015

Ongoing studies by the German CLL study group (GCLLSG)

At the 20th Congress of the European Hematology Association (EHA), Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany, discusses…
3rd July 2015

HELIOS: Phase 3 trial of ibrutinib in previously treated CLL/SLL

At the 20th Congress of the European Hematology Association (EHA), Paula Cramer, MD, of the University Hospital Cologne, Cologne, Germany, discusses the…
EMJ
6 Mins
3rd July 2015

STELARA® Receives European Commission Approval for Treatment of Adolescents with Moderate-To-Severe Psoriasis in Europe

Beerse, Belgium, 29 June 2015 – Janssen-Cilag International NV (“Janssen”) announced today that the European Commission (EC) has approved STELARA®…
EMJ
3rd July 2015

Animation Demonstrating Implantation of the CARILLON Device

Treatment of Secondary Mitral Regurgitation via Percutaneous Annuloplasty
EMJ
3rd July 2015

Video of Patient Case Showing Real-Time Implantation of the CARILLON Device

Treatment of Secondary Mitral Regurgitation via Percutaneous Annuloplasty: Video of Patient Case Showing Real-Time Implantation of the CARILLON Device.
EMJ
8 Mins
3rd July 2015

Studies Confirm Regorafenib Benefit in Pre-Treated Metastatic Colorectal Cancer

BARCELONA-LUGANO, 3 July 2015 – The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated…
EMJ
4 Mins
2nd July 2015

Patients with Lowest BMI Have Shortest Survival in Pooled Analysis of Bevacizumab in Metastatic Colorectal Cancer

BARCELONA-LUGANO, 1 July 2015 – Patients with the lowest body mass index (BMI) had the shortest overall survival in an analysis of bevacizumab studies
EMJ
5 Mins
2nd July 2015

SENRI Trial Opens Window to Evaluate NK1 Antagonists for Emesis Prevention in Oxaliplatin Chemotherapy

BARCELONA-LUGANO, 1 July 2015 – The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin…
EMJ
1 Mins
29th June 2015

Immune System Response Directed by ‘Gut Reaction’ to Illness

SIGNAL projection from cells in the infected guts of mice influences the programming of immune system cells to either repair or protect the body…